

					

						November 19, 2017 - By Peter Erickson
Among 16 analysts covering Acceleron Pharma (NASDAQ:XLRN), 11 have Buy rating, 1 Sell and 4 Hold. Therefore 69% are positive. Acceleron Pharma had 34 analyst reports since August 13, 2015 according to SRatingsIntel. The stock has “Neutral” rating by Janney Capital on Thursday, December 17. Oppenheimer downgraded the shares of XLRN in report on Tuesday, June 13 to “Market Perform” rating. The firm has “Hold” rating given on Thursday, September 21 by Credit Suisse. The stock of Acceleron Pharma Inc (NASDAQ:XLRN) has “Buy” rating given on Thursday, March 2 by Citigroup. The stock has “Overweight” rating by Morgan Stanley on Thursday, August 13. Oppenheimer reinitiated the stock with “Outperform” rating in Monday, February 1 report. The stock of Acceleron Pharma Inc (NASDAQ:XLRN) has “Outperform” rating given on Thursday, January 21 by Credit Suisse. FBR Capital maintained it with “Outperform” rating and $63 target in Monday, January 18 report. The firm has “Overweight” rating by Barclays Capital given on Wednesday, April 27. The stock has “Overweight” rating by Barclays Capital on Monday, June 13. See Acceleron Pharma Inc (NASDAQ:XLRN) latest ratings:14/11/2017 Broker: Credit Suisse Rating: Outperform Old Target: $35 New Target: $51 Maintain02/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $44.0 Maintain12/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $57 Initiates Coverage On06/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $40.0 Maintain21/09/2017 Broker: Credit Suisse Rating: Hold New Target: $35.0 Downgrade20/09/2017 Broker: Barclays Capital Rating: Overweight Old Target: $42 New Target: $50 Maintain15/09/2017 Broker: RBC Capital Markets Rating: Sector Perform New Target: $44 Initiates Coverage On12/09/2017 Broker: UBS Rating: Buy New Target: $50.0 Maintain04/08/2017 Broker: Credit Suisse Rating: Buy New Target: $35.0000 04/08/2017 Broker: Citigroup Rating: Buy New Target: $44.0000 Hexavest Inc increased Ambev Sa Util (ABEV) stake by 43.06% reported in 2017Q2 SEC filing. Hexavest Inc acquired 201,494 shares as Ambev Sa Util (ABEV)’s stock declined 1.05%. The Hexavest Inc holds 669,457 shares with $3.68 million value, up from 467,963 last quarter. Ambev Sa Util now has $98.08B valuation. The stock increased 1.30% or $0.08 on November 17, reaching $6.24. About 17.12 million shares traded. Ambev SA (ADR) (NYSE:ABEV) has risen 10.52% since November 19, 2016 and is uptrending. It has underperformed by 6.18% the S&P500.Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $1.70 billion. The Firm is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. It currently has negative earnings. The Company’s research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta , protein superfamily.The stock increased 4.71% or $1.74 on November 17, reaching $38.71. About 284,820 shares traded. Acceleron Pharma Inc (NASDAQ:XLRN) has declined 22.43% since November 19, 2016 and is downtrending. It has underperformed by 39.13% the S&P500.Investors sentiment increased to 1.44 in Q2 2017. Its up 0.51, from 0.93 in 2017Q1. It is positive, as 16 investors sold Acceleron Pharma Inc shares while 27 reduced holdings. 17 funds opened positions while 45 raised stakes. 33.54 million shares or 7.21% more from 31.29 million shares in 2017Q1 were reported. C Grp Incorporated Hldg A S reported 4,539 shares stake. Gru Inc has invested 0% in Acceleron Pharma Inc (NASDAQ:XLRN). California State Teachers Retirement System invested in 56,795 shares or 0% of the stock. The New York-based Sg Americas Lc has invested 0% in Acceleron Pharma Inc (NASDAQ:XLRN). Quantbot Technology Limited Partnership stated it has 565 shares or 0% of all its holdings. Qvt Financial L P has invested 0.39% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN). Moreover, Legal General Grp Inc Pcl has 0% invested in Acceleron Pharma Inc (NASDAQ:XLRN) for 10,470 shares. Td Asset Management Inc reported 78,800 shares stake. Guggenheim Cap Llc, Illinois-based fund reported 66,474 shares. Manufacturers Life Insurance The invested in 25,204 shares or 0% of the stock. Meeder Asset Management holds 254 shares or 0% of its portfolio. Citadel Advsr Lc invested 0% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN). Vanguard Group reported 2.03 million shares stake. Massachusetts-based Harbourvest Prtn has invested 0.67% in Acceleron Pharma Inc (NASDAQ:XLRN). Hillhouse Capital Mgmt invested in 0.33% or 700,000 shares.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

		var data = "63557954";
		document.write('<ins class="adsbygoogle" style="background-color:transparent; display:inline-block;width:300px;height:600px;" data-ad-client="ca-pub-16900'+data+'675" data-ad-slot="1262194147"></ins>')
	
(adsbygoogle = window.adsbygoogle || []).push({});